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Purpose: Overexpression of TP53INP1 induces G1 cell cycle arrest and increases p53-mediated 
apoptosis. To clarify the clinical importance of TP53INP1, we analyzed TP53INP1 and p53 expression in 
gastric cancer.  
Experimental Design: TP53INP1 and p53 expression were examined using immunohistochemistry on 
142 cases of gastric cancer. The apoptosis of gastric cancer cells was analyzed using the TUNEL method.  
Results: TP53INP1 was expressed in 98% (139/142 cases) of non-cancerous gastric tissues and 
was down-expressed in 64% (91/142 cases) of gastric cancer lesions from the same patients. TP53INP1 
expression was significantly decreased (43.9%) in poorly differentiated adenocarcinoma compared with 
well or moderately differentiated adenocarcinoma (81.6%). Cancers invading the submucosa or deeper 
showed lower positively (59.1%) compared with mucosal cancers (85.2%). Decrease or loss of TP53INP1 
expression was significantly correlated with lymphatic invasion (54.3% vs 82.0% without lymphatic 
invasion) and node-positive patients (31.3% vs 68.3% in node-negative patients). P53 was expressed in 68 
(47.9%) patients of gastric cancer, whereas it is absent in normal gastric tissues. A significant association 
was also observed between TP53INP1 status and the level of apoptosis in tumoral cells: the apoptotic index 
in TP53INP1-positive tissues was significantly higher than that in TP53INP1-negative portions. Finally, 
when survival data were analyzed, loss of TP53INP1 expression had a significant effect 
on predicting a poor prognosis (p=0.0006).  
Conclusions: TP53INP1-positive rate decreased with the progression of gastric 
cancer. TP53INP1 protein negativity was significantly associated with 
aggressive pathological phenotypes of gastric cancer. TP53INP1 
was related to the apoptosis of gastric cancer cells. The decreased expression 
of the TP53INP1 protein may reflect the malignant grade of gastric cancer and is regarded 
as an adverse prognostic factor.  
 




Tumor Protein 53-Induced Nuclear Protein 1 (TP53INP1) 
is a p53-inducible gene encoding two protein isoforms able to modulate p53 biological 
activities (1-4). TP53INP1 expression is strongly induced in vivo in mice with acute pancreatitis (1), 
and in vitro in several cell lines submitted to various stress agents (2，4). Over-expression 
of TP53INP1 induces cell cycle arrest in G1 phase and enhances the p53-mediated 
apoptosis (3). TP53INP1 co-localizes with p53 and the serine-threonine p53-kinase HIPK2 (5) 
within the promyelocytic leukemia protein nuclear bodies (PML-NBs) 
and physically interacts with these proteins modifying the p53 transcriptional activity on 
several p53 target genes (3). TP53INP1 thus appears as a key-element in p53-mediated cell death 
and cell cycle arrest, induced by cellular stresses. 
The multistep model of carcinogenesis in gastric cancer, the second most common 
cancer leading death in the world, suggests accumulation of genetic alterations, epigenetic 
changes and posttranslational modifications. It often metastasizes to other organs, 
including liver, lung, and ovary (6). Multiple factors are known to be related to gastric 
carcinogenesis, including Epstein-Barr virus (7) and Helicobacter pylori infections (8), 
microsatellite instability (9). From the molecular point of view, it has now been established that 
gastric carcinogenesis involved accumulation of mutations in oncogenes and tumor suppressor 
genes controlling epithelial cell growth and differentiation (10-14). In particular, TP53 
mutations are frequently seen in gastric cancers and correlates with gastric cancer prognosis (15, 
16). However, the molecular alterations and their role in gastric cancer 
still remain to be fully defined.  
Previous works implied that TP53INP1 is a proapoptotic gene induced by p53 (2). 
Overexpression of TP53INP1 promotes G1 arrest and 
apoptosis through the p53-mediated pathway (3). The aim of the present 
study was to analyze the expression patterns of TP53INP1 in a large series of gastric 
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carcinomas to (1) identify the possible modulation of TP53INP1 expression; (2) 
investigate the association with apoptotic activity; (3) analyze the relationship with 
clinicopathologic parameters, and evaluate its prognostic value. 
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MATERIALS AND METHODS 
Patients and Specimens. One hundred and forty-two patients with gastric cancer 
were enrolled in this study. The areas adjacent to cancer lesions were used as non-malignant 
gastric tissue. The patients underwent operation 
at the Cancer Research Institute Hospital, Kanazawa University. The histological classification 
was defined using the Japanese classification of gastric carcinoma (17). Intestinal type was defined 
as either papillary or well to moderately differentiated tubular 
adenocarcinoma. Diffuse type was defined as poorly differentiated adenocarcinoma, 
signet-ring cell carcinoma, or mucinous adenocarcinoma. The series included 104 men and 38 
women, and the mean age was 63.1±10.6 years. There were 76 and 66 cases of differentiated and 
undifferentiated type, respectively.  
Immunohistochemistry. A standard avidin-biotin-peroxidase complex method (ABC) 
was used for immunostaining. Deparaffinized sections were treated by microwaving at 
a high power for 5 min two times in a 10 mM citrate buffer to retrieve antigenicity. After 
washing with PBS, the sections were immersed in 3% hydrogen peroxide in methanol for 20 
min to block any endogenous peroxides activity. Then the ABC staining system kit 
(Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) was used for 
detection. Sections were incubated with 10% normal serum for 1 hour to inhibit nonspecific 
antibody binding. Then, sections were incubated overnight at 4ºC with 6µg/ml of rat anti-human 
monoclonal antibody raised against to TP53INP1 (kindly provided by A. Carrier). After 
washing with PBS, detection was done by successively incubating the sections with biotinylated 
goat anti-rat IgG for 30 min, and avidin-biotin-HRP for 30 min. After extensive washings with PBS, 
sections were stained with 3-diaminobenzidine for 2~10 min. Then, sections were counterstained 
with hematoxylin, dehydrated, and mounted. Nuclei were lightly counterstained with 
Mayer’s hematoxylin. TP53INP1-positive cells were counted in fields chosen at random (100× 
magnification), and the percentage of the number of positive cells per 1,000 cells was expressed 
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as TP53INP1-positive index (%). Use the same method 
we counted the TP53INP-positive in nucleus and in cytoplasm under the microscopy with a 200 
magnifying. The Normal IgG was used as a negative control.  
P53 was immunolocalized using a DAKO LSAB kit 
(DakoCytomation, Japan, Kyoto, Japan). The primary antibody was rabbit monoclonal 
antibody against human p53 
(Nichirei Inc, Tokyo, Japan). The procedure was according to the protocol from company. Final t
he sections were incubated with DAB substrate as a 
chromogen. The cell nuclei were also lightly counterstained with Mayer hematoxylin. 
Terminal deoxynucleotidyl transferase-mediated 
dUTP nick end labeling (TUNEL). TUNEL-positive epithelial cells were detected 
on the sections using ApopTag Plus peroxides in situ apoptosis detection kit 
(Chemicon International, Inc., Temecula, CA, USA). Briefly, after pretreatment with 20 μg/ml 
of proteinase K and 3% hydrogen peroxide, sections were incubated with a labeling mixture for 
1 hour at 37ºC. Then 55 μl of anti-digoxigenin-peroxidase were deposited on sections and 
incubated for 30 minutes. The reaction products were visualized by 3,3-diaminobenzidine substrate. 
Nuclei were counterstained with methy1 green for 10 minutes. After 
washing with n-butanol, the sections were dehydrated, and mounted. Apoptotic index (%) 
corresponding to the number of labeled nuclei per 1,000 nuclei was calculated. 
Statistical Analyses. Experimental results were expressed as mean 
± SEM. Difference between the means was evaluated by the Mann-Whitney U test. P < 0.05 
was considered as statistically significant. The statistical analysis in this paper such 
as Kaplan-Meier analysis and Cox regression model was performed 





TP53INP1 was expressed in non-malignant gastric tissues and its expression 
was reduced in gastric cancer tissues. In the non-neoplastic gastric mucosa, TP53INP1 
was mainly located in the cytoplasm of epithelial cells (Fig. 1A and 
1B). Some nuclei were also stained for TP53INP1 (Fig. 2). Similar patterns were observed for 
intestinal metaplasia samples (Fig. 1A, insert). To determine if TP53INP1 
is differentially expressed in gastric carcinomas or if it is stage-related, we did 
immunohistochemical analysis on 142 samples (76 cases of intestinal type, and 66 cases of 
diffuse type). All the cancer samples had accompanying non-malignant tissues, 98% 
of them were positive with TP53INP1 expression (Table 1) and thus could be used as internal 
control. In contrast, the expression of TP53INP1 protein was seen in 91 cases (64%) 
showed TP53INP1 staining, the other 51 samples (36%) were found TP53INP1-negative (Fig. 1B, 
arrow). Overall, TP53INP1 expression in gastric cancers was significantly lower both in cell 
cytoplasm and nucleus than in non-malignant gastric tissue (p<0.0001, Table1; Fig. 
2). However, the expression of TP53INP1 was decreased in well-differentiated tubular 
adenocarcinoma (Fig. 1C), and was markedly diminished in poorly differentiated-type cancer (Fig. 
1D). 
We next examined whether TP53INP1 expression is associated or not with development 
and progression of gastric carcinoma. The clinical details of the cohort of patients and the statistical 
analysis are listed in Table 2. Only two non significant associations were observed, i.e., age and 
gender. TP53INP1 negativity was associated with gastric body and antrum tumor location 
(p=0.0193), with poorly differentiated adenocarcinoma (diffuse type) (p<0.0001). 
With regard to the depth of invasion, the positive TP53INP1 expression rate was 100% 
intramucosal tumors (5/5), 81.8% when mucosa was invaded (18/22), 76.5% in muscularis propria 
(26/34), 54.3% in subserosa (25/46), and 48.6% in serosa (17/35). These results clearly show that 
alteration of TP53INP1 expression 
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was correlated to the staging of the tumors. The difference was statistically significant 
when T1 tumors were compared to the other stages (p=0.0111, Table 2). In addition, TP53INP1 
was significantly expressed in node-negative patients (p=0.0037), and significantly associated 
with lymphatic 
invasion-negative patients (p=0.0010). Taken together, these results indicated that loss of TP53IN
P1 expression was significantly associated with poorly differentiated histology, deep 
invasion, lymph node invasion, and metastasis.  
 
TP53INP1 and apoptosis. TP53INP1 modulates the cell cycle arrest and programmed cell 
death (3). To investigate whether the modulation of TP53INP1 expression is associated with 
differences in apoptotic activity, TUNEL assays were done in all the 142 
cases. TUNEL-positive nuclei were clearly seen in TP53INP1- positive (Fig. 3A) and negative (Fig. 
3B) cancer lesions. As shown in Fig. 3C, the apoptotic index in the TP53INP1-positive group 
(7.48%±2.66%) was significantly higher than that found in the TP53INP1-negative group (4.16%
±2.41%). 
TP53INP1 expression and prognosis. On univariate analysis, patient survival 
according to pathological stage was significantly different 
between TP53INP1- positive and TP53INP1- negative groups. Those patients with TP53INP1- po
sitive expression had significantly better survival than those without TP53INP1 expression 
(p=0.0006, Fig. 4A). Survival for TP53INP1- positive patients with poorly differentiated 
adenocarcinoma was significantly longer than that of TP53INP1- negative patients (p=0.0199, Fig. 
4B), whereas the survival of TP53INP1- positive patients in well or moderately differentiated 
adenocarcinoma was not significantly different from that 
of TP53INP1- negative patients (p=0.1110, Fig. 4C). Taken together, the results indicate that 
alteration of TP53INP1 expression was associated with a poor prognosis. 
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Nevertheless, no prognostic value for TP53INP1 expression 
was evidenced from the multivariate analysis (Table 3). Histological type, apoptotic index, 
metastasis, and lymph node invasion were the most important 
independent prognostic factors, TP53INP1 could not be considered as an independent prognostic 
marker. 
P53 was not expressed in non-malignant gastric tissues and was expressed in gastric 
cancer tissues. AS show on Table 1 and figure 1E, the p53 protein was expressed in gastric 
cancer regions whereas it’s absent 
in non-malignant portions. The staining was nuclear. Cytoplasmic staining without nuclear 
staining was regarded as negative. The p53 positive rate in gastric cancer was 47.9% that 




The development and progression of gastric cancer involves many types of 
genes that need to be activated or inactivated in order to promote malignancy. Gastric cancer 
is a heterogeneous pathology, classified into 2 general subtypes: intestinal (differentiated) and 
diffuse (undifferentiated) (17). The intestinal type gastric carcinoma presents tumor suppressor 
gene alterations similar to colorectal tumors and distinct from diffuse type gastric cancer (18). An 
accumulation of multiple genetic and epigenetic alterations of oncogenes, tumor suppressor 
genes, DNA repair genes, cell cycle regulators, cell adhesion molecules, and growth factor/receptor 
systems are involved during the multistep conversion from normal epithelial cells to clinical gastric 
cancer (10-14). TP53 gene alterations have been observed in both histological 
subtypes (19). TP53INP1 is a tumor suppressor gene, located on the chromosome band 8q22 
(20). Its expression is dependent on the activation of wide-type p53 (3). 
 In this study, we showed that TP53INP1 protein expression was significantly reduced in 
gastric cancer cells compared with non-cancerous adjacent tissues. 
We also reported that reduced TP53INP1 expression was associated 
with the diffuse cancer phenotype. Tomasini et al. (2) have shown that TP53INP1 and HIPK2 
are partners in regulating p53 activity. It is increasingly evident that methylation of CpG 
islands in the promoter of specific tumor suppressor genes, such as p16, is associated with their 
silencing in human gastric cancer (21). The 5′-upstream region of TP53INP1 contains a CpG 
island. The sequences from nucleotide-792, the region on exon 1 and part of the first 
intron, to nucleotide +839, has the highest content of CpG 
dinucleotides. However, there is no mutation of TP53INP1 gene in pancreatic carcinoma 
(unpublished data). In addition, the reduced TP53INP1 expression in gastric cancer 
especially in the diffuse type may relate to the wide type p53 inactivation in gastric cancer.  
We showed p53 was expressed in 68 cases of gastric cancer, whereas it was not present 
in normal gastric epithelial. We observed that in non-gastric cancer regions the expression 
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of TP53INP1 was opposite to that of p53. The expression of TP53INP1 was dependent 
on the wild type p53. Since the wild-type p53 protein is biologically unstable and has a 
shorter half-life than mutant p53 protein (24). This characteristic of wide-type p53 protein does not 
allow it detected by immunohistochemical, but mutant p53 can be detected by immunostaining. 
Our data was similar to Carvalho et al. (22) showed that there is no different of the p53 expression 
between the intestinal type and the diffuse type in gastric cancer. Whereas Lin et al (23) 
showed the expression of p53 in the intestinal type is more frequent than that in 
diffuse type. The precise mechanisms of TP53INP1 suppression in gastric 
cancer need further research. 
The mechanism of the suppression of these genes in poorly differentiated gastric carcinoma 
is not clear. Many studies suggested that most tumor suppressor genes play a role in 
mediating cell cycle arrest in the G1 phase following DNA damage and also function 
in the removal of damaged cells by initiating apoptosis in certain physiological 
situations (10). TP53INP1 and HIPK2 are partners in regulating p53 activity (2). Overexpression 
of TP53INP1 induces G1 cell cycle arrest. TP53INP1 expression was significantly decreased in 
advanced gastric cancers. These results suggest that decrease of TP53INP1 expression 
might play an important role in the progression of gastric cancer. Assessment of TP53INP1 
expression level may serve as a novel biomarker for predicting the malignant grade of 
cancers, like another marker for poor prognosis genes (25, 26).  
Lymphatic involvement is thought to be important as an initial step 
of lymph node metastasis (27). Our study showed that TP53INP1 expression 
was significantly reduced in lymphatic invasion-positive groups. TP53INP1 expression decreased 
in node-positive. Taken together, these results suggested that loss of TP53INP1 expression 
is associated with lymph node metastasis of gastric cancer. 
Deregulation of genes involved in cell cycle and cell signaling pathways has been described 
and classified as early events for cyclin D1 and p16 genes or late events for p53, DPC4 and BRCA2 
JIANG-12 
 
genes in the progression model studies (28). TP53INP1 is a proapoptotic gene strongly activated 
during cell stress. Overexpression of TP53INP1 is related to G1 cell cycle arrest and 
induces p53-mediated cell death (3). In the present study, we showed that the apoptotic index 
in TP53INP1-positive lesions was higher than that in TP53INP1-negative lesions in gastric 
cancer tissues by TUNEL detection, indicating that TP53INP1 is related to apoptosis and tumor 
aggressiveness in gastric carcinoma.  
TP53INP is an acute gene that induced by various stress such as UV, heat shock et al 
(1). Up to now, we have known little function of it. We for the first time revealed impact 
of the TP53INP1 on the survival in gastric cancer. 
We showed the survival rate of the TP53INP1-positive cases was longer than that 
of the TP53INP1-negative cases, especially in the diffuse type.  
In conclusion, the present study showed that the reduction of TP53INP1 expression 
might play roles in gastric carcinogenesis and tumor aggressiveness. Analysis of the TP53INP1 
may be useful to evaluate the malignant grade of gastric cancer.  
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Figure 1. Immunohistochemical analysis of TP53INP1 expression in gastric 
carcinoma. A: TP53INP1 was strongly expressed in normal gastric mucosa or intestinal 
metaplasia foci (inset). B: TP53INP1 expression decreased in gastric carcinoma (arrow). C: Well 
differentiated tubular carcinoma exhibited moderate alteration of TP53INP1 expression. D: 
Poorly differentiated carcinoma showed weakly staining with TP53INP1 antibody. E: P53 
expression increased in gastric carcinoma (arrow). 
Figure 2. Comparison of TP53INP1 expression (in cell cytoplasm and nucleus) between normal 
gastric mucosa and gastric cancer tissues (* p<0.0001). 
Figure 3. Apoptosis analysis in gastric cancer. A 
and B: Representative patterns of TP53INP1-positive (A) and negative (B) carcinoma in TUNEL 
staining. Arrows indicate TUNEL-positive nuclei (original magnification × 20). C: Statistical 
analysis of apoptotic index in TP53INP1-positive and -negative cancer tissues (* p<0.0001).  
Figure 4. TP53INP1 expression and patient survival by Kaplan-Meier analysis. A: Survival 
curves for TP53INP1-positive and negative gastric 
cancers. The 60-months survival rates are 74.7% and 
54.9%, respectively. The difference between the values is highly significant (p=0.0006). B: In well 
or moderately differentiated adenocarcinoma (intestinal-type), the survival 
of TP53INP1-positive patients was not significantly different from that 
of TP53INP1-negative group (p=0.1110). C: In poorly differentiated adenocarcinoma 
(diffuse-type), the 60-months patient survival rates are 62.1% and 
45.9% for TP53INP1-positive and -negative gastric 
cancers, respectively. This difference is statistically significant (p=0.0199). 
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Table 1 TP53INP1 expression in gastric cancer 
  Non-malignant  




TP53INP1 Positive 139 (98%) 91 (64%)  <0.0001 
 Negative 3 (2%) 51 (36%)  
P53 Positive 0 (0%) 68 (47.9%) <0.0001 
 Negative 142 (100%) 74 (52.1%)  
*: In gastric cancer the p value between TP53INP1 and P53 was 0.006. 
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Table 2. Correlation between TP53INP1 expression levels and clinicopathologic 
features in gastric cancer 
 TP53INP1-positive
(n=91 of 142 
patients) 
TP53INP1-negative 
(n=51 of 142 
patients) 
p value 
Age (years)    
 <60 31 18 NS 
 ≧60 60 33  
Sex    
  Male 68 36 NS 
  Female 23 15  
Location    
  Cardia 20 22  
  Body 58 26 0.0193 
  Antrum 13 3  
Histological type    
  Differentiateda  62 14  
  Undifferentiatedb 29 37 <0.0001 
Tumor invasion    
T1a+T1b 23 4 0.0111 
T2+T3+T4 68 47  
Lymph node 
metastasis 
   
  Positive 5 11 0.0037 
  Negative 86 40  
Metastasis    
  Positive 0 5 0.0024 
  Negative 91 46  
Lymphatic invasion    
  Positive 50 42 0.0010 
  Negative 41 9  
NS: not significant 
aDifferentiated type corresponds to well and moderately differentiated tubular and 
papillar tumors (intestinal type) 






Table 3 Multivariate survival analysis using the Cox regression model 
 
factor Reference Odds Ratio p 
TP53INP1 + vs - 1.250 0.3680 
Age <60 vs ≥60 1.388 0.1077 
Gender Male vs female 1.158 0.5217 
Location Body+cardia vs autrum 1.253 0.4847 
Histological type Poor vs well+moderately 2.043 0.0026 
Tumor invasion T2+T3+T4 vs T1 1.061 0.8485 
Stage Ⅲ+Ⅳ vs Ⅱ+Ⅰ 1.269 0.2612 
Apoptotic index ≤4% vs >4% 2.244 0.0008 
Metastasis + vs - 18.688 0.0007 
Lymphatic invasion + vs - 0.721 0.2124 
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